94 related articles for article (PubMed ID: 28604448)
1. MAP2K6-FP Enhances the Sensitiveness of Paclitaxel for Ovarian Cancer via Inducing Autophagy.
Guo Y; Yuan J; Yin S; Wang X; Shuai R; Kang J
Int J Gynecol Cancer; 2017 Jul; 27(6):1082-1087. PubMed ID: 28604448
[TBL] [Abstract][Full Text] [Related]
2. Mitogen-activated Protein Kinase Kinase 6-fusion Protein (MAP2K6-FP) Potentiates the Anti-tumor effects of Paclitaxel in Ovarian Cancer.
Yuan J; Kang JL; Liao H; Wang XX; Nie ML; Shuai R; Deng C
Anticancer Agents Med Chem; 2015; 15(10):1308-16. PubMed ID: 26118713
[TBL] [Abstract][Full Text] [Related]
3. Delivery of Constitutively Active Mutant MKK6(E) With TAT-OSBP Induces Apoptosis in Human Ovarian Carcinoma HO8910 Cells.
Liao H; Kang JL; Jiang WY; Deng C; Yuan J; Shuai R
Int J Gynecol Cancer; 2015 Nov; 25(9):1548-56. PubMed ID: 26495757
[TBL] [Abstract][Full Text] [Related]
4. TAT-OSBP-1-MKK6(E), a novel TAT-fusion protein with high selectivity for human ovarian cancer, exhibits anti-tumor activity.
Zhong J; Kang J; Wang X; Jiang W; Liao H; Yuan J
Med Oncol; 2015 Apr; 32(4):118. PubMed ID: 25782870
[TBL] [Abstract][Full Text] [Related]
5. TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer.
Zhang SF; Wang XY; Fu ZQ; Peng QH; Zhang JY; Ye F; Fu YF; Zhou CY; Lu WG; Cheng XD; Xie X
Autophagy; 2015; 11(2):225-38. PubMed ID: 25607466
[TBL] [Abstract][Full Text] [Related]
6. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
7. Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.
Wang J; Garbutt C; Ma H; Gao P; Hornicek FJ; Kan Q; Shi H; Duan Z
Gynecol Oncol; 2018 Jul; 150(1):143-150. PubMed ID: 29699801
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
Xiao J; Xu M; Hou T; Huang Y; Yang C; Li J
Mol Med Rep; 2015 Sep; 12(3):3249-3256. PubMed ID: 25975261
[TBL] [Abstract][Full Text] [Related]
9. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
10. Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer.
Alagkiozidis I; Gorelick C; Shah T; Chen YA; Gupta V; Stefanov D; Amarnani A; Lee YC; Abulafia O; Sarafraz-Yazdi E; Michl J
Ann Clin Lab Sci; 2017 May; 47(3):271-281. PubMed ID: 28667027
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
[TBL] [Abstract][Full Text] [Related]
12. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
[TBL] [Abstract][Full Text] [Related]
13. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.
Dietrich CS; Greenberg VL; DeSimone CP; Modesitt SC; van Nagell JR; Craven R; Zimmer SG
Gynecol Oncol; 2010 Jan; 116(1):126-30. PubMed ID: 19875160
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Modesitt SC; Parsons SJ
Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
[TBL] [Abstract][Full Text] [Related]
15. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
Li Y; Chen K; Li L; Li R; Zhang J; Ren W
Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
[TBL] [Abstract][Full Text] [Related]
17. [Effects of DCC gene on cell growth and chemosensitivity of ovarian epithelial carcinoma cells].
Zhuang RJ; Li PL; Yu HW; Li HM
Zhonghua Fu Chan Ke Za Zhi; 2007 May; 42(5):334-8. PubMed ID: 17673047
[TBL] [Abstract][Full Text] [Related]
18. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.
Yang YI; Lee KT; Park HJ; Kim TJ; Choi YS; Shih IeM; Choi JH
Carcinogenesis; 2012 Dec; 33(12):2488-98. PubMed ID: 23027625
[TBL] [Abstract][Full Text] [Related]
19. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
Stamelos VA; Robinson E; Redman CW; Richardson A
Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
[TBL] [Abstract][Full Text] [Related]
20. Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.
Haltia UM; Andersson N; Yadav B; Färkkilä A; Kulesskiy E; Kankainen M; Tang J; Bützow R; Riska A; Leminen A; Heikinheimo M; Kallioniemi O; Unkila-Kallio L; Wennerberg K; Aittokallio T; Anttonen M
Gynecol Oncol; 2017 Mar; 144(3):621-630. PubMed ID: 28104295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]